Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets

Altay, 2007, Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients, J. Orthop. Sci., 12, 415, 10.1007/s00776-007-1152-z Altieri, 2006, The case for survivin as a regulator of microtubule dynamics and cell-death decisions, Curr. Opin. Cell Biol., 18, 609, 10.1016/j.ceb.2006.08.015 Amary, 2011, IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours, The J. Pathology, 224, 334, 10.1002/path.2913 Azzi, 2014, Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis, Curr. Opin. Oncol., 26, 403, 10.1097/CCO.0000000000000092 Bakker, 1999, 99mTc-sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours, Anticancer Res., 19, 2349 Bao, 2017, Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth, Cell. Death & Dis., 8, 10.1038/cddis.2017.31 Björnsson, 1998, Primary chondrosarcoma of long bones and limb girdles, Cancer, 83, 2105, 10.1002/(SICI)1097-0142(19981115)83:10<2105::AID-CNCR9>3.0.CO;2-U Bovée, 2008, Multiple osteochondromas, Orphanet. J. Rare Dis., 3, 3, 10.1186/1750-1172-3-3 Bovée, 1999, Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis, J. Pathol., 189, 454, 10.1002/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N Bovée, 2005, Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment, Lancet Oncol., 6, 599, 10.1016/S1470-2045(05)70282-5 Brien, 1999, Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors, Skeletal Radiol., 28, 1, 10.1007/s002560050466 Bui, 2010, Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells, FASEB J., 24, 436, 10.1096/fj.09-136291 Castresana, 1992, Amplification of the c-myc proto-oncogene in human chondrosarcoma, Diagn. Mol. Pathol.: Am. J. Surg. Pathol. Part B, 1, 235, 10.1097/00019606-199203000-00035 Cesari, 2007, Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution, Tumori, 93, 423, 10.1177/030089160709300503 Chen, 2010, Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo, Apoptosis, 15, 805, 10.1007/s10495-010-0489-5 Chen, 2014, MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD, Exp. Cell. Res., 320, 12, 10.1016/j.yexcr.2013.10.014 Cheong, 2011, Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines, Cancer Res. Treat., 43, 124, 10.4143/crt.2011.43.2.124 Chevalier, 2015, Proteomic overview and perspectives of the radiation-induced bystander effects, Mutat. Res. Rev. Mutat. Res., 763, 280, 10.1016/j.mrrev.2014.11.008 Cleton-Jansen, 2005, Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma, Clin. Cancer Res., 11, 8028, 10.1158/1078-0432.CCR-05-1253 Dang, 2010, IDH mutations in glioma and acute myeloid leukemia, Trends Mol. Med., 16, 387, 10.1016/j.molmed.2010.07.002 Dantonello, 2008, Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults, Cancer, 112, 2424, 10.1002/cncr.23457 David, 2011, The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets, Sarcoma Dickey, 2004, Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes, JBJS, 86, 2412, 10.2106/00004623-200411000-00008 Drilon, 2008, Extraskeletal myxoid chondrosarcoma, Cancer, 113, 3364, 10.1002/cncr.23978 Duan, 2009, ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines, PLoS One, 4, e6967, 10.1371/journal.pone.0006967 Easwaran, 2014, Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance, Mol. Cell, 54, 716, 10.1016/j.molcel.2014.05.015 Evans, 1977, Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading, Cancer, 40, 818, 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B Fiorenza, 2002, Risk factors for survival and local control in chondrosarcoma of bone, Bone Jt. J., 84, 93, 10.1302/0301-620X.84B1.11942 Fletcher, 2002, vol. 4 Fong, 2007, 2‐methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells, J. Orthop. Res., 25, 1106, 10.1002/jor.20364 Franchi, 1998, Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton, Virch. Archiv., 432, 515, 10.1007/s004280050199 Frezza, 2015, Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study, Eur. J. Cancer, 51, 374, 10.1016/j.ejca.2014.11.007 Fu, 2015, Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling, J. Hepatol., 63, 886, 10.1016/j.jhep.2015.05.016 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703 Gamie, 2017, TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data, Cancer Lett., 409, 66, 10.1016/j.canlet.2017.08.036 Gelderblom, 2008, The clinical approach towards chondrosarcoma, Oncologist, 13, 320, 10.1634/theoncologist.2007-0237 Giuffrida, 2009, Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database, JBJS, 91, 1063, 10.2106/JBJS.H.00416 GrØnbÆk, 2007, Epigenetic changes in cancer, Apmis, 115, 1039, 10.1111/j.1600-0463.2007.apm_636.xml.x Guilhamon, 2013, Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2, Nat. Commun., 4, 2166, 10.1038/ncomms3166 Hamm, 2009, Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2′-deoxycytidine results in increased tumorigenicity, PLoS One, 4, e8340, 10.1371/journal.pone.0008340 Herbst, 2010, Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer, J. Clin. Oncol., 28, 2839, 10.1200/JCO.2009.25.1991 Heymann, 2011, Bone sarcomas: pathogenesis and new therapeutic approaches, IBMS Bone KEy, 8, 402, 10.1138/20110531 Heymann, 2013, Targeted therapies for bone sarcomas, Bonekey Rep., 2, 378, 10.1038/bonekey.2013.112 Ho, 2009, Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors, Cancer Cell., 16, 126, 10.1016/j.ccr.2009.05.013 Horak, 2005, Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer, Mol. Cancer Res., 3, 335, 10.1158/1541-7786.MCR-04-0136 Hua, 2014, Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A, Oncol. Rep., 31, 2727, 10.3892/or.2014.3156 Huang, 2017, Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells, Cancer Biomark., 18, 231, 10.3233/CBM-160102 Jamil, 2016, Functional roles of CSPG4/NG2 in chondrosarcoma, Int. J. Exp. Pathol., 97, 178, 10.1111/iep.12189 Jemal, 2010, Cancer statistics, 2010, CA. Cancer J. Clin., 60, 277, 10.3322/caac.20073 Jiang, 2016, The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2, Tumor Biol., 37, 5933, 10.1007/s13277-015-4454-3 Kerr, 2013, Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations, Am. J. Surg. Pathol., 37, 787, 10.1097/PAS.0b013e31827ab703 Kim, 2007, Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of grade II chondrosarcoma cells, J. Orthop. Res., 25, 820, 10.1002/jor.20377 Kim, 2009, siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells, Mol. Cancer, 8, 28, 10.1186/1476-4598-8-28 Kumari, 2012, The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance, Carcinogenesis, 33, 2076, 10.1093/carcin/bgs254 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Lechler, 2011, The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro, BMC Cancer, 11, 120, 10.1186/1471-2407-11-120 Leerapun, 2007, Surgical management of conventional grade I chondrosarcoma of long bones, Clin. Orthop., 463, 166, 10.1097/BLO.0b013e318146830f Liu, 2010, Cyclooxygenase-2 enhances α2β1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells, Mol. Cancer, 9, 43, 10.1186/1476-4598-9-43 Liu, 2015, CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells, Cancer Lett., 357, 476, 10.1016/j.canlet.2014.11.015 Liu, 2016, Aberrant DNA methylations in chondrosarcoma, Epigenomics, 8, 1519, 10.2217/epi-2016-0071 Lu, 2012, IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, 483, 474, 10.1038/nature10860 Lu, 2015, Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma, Tumor Biol., 36, 3843, 10.1007/s13277-014-3026-2 Mak, 2015, The epigenetic regulation of SOX9 by miR‐145 in human chondrosarcoma, J. Cell. Biochem., 116, 37, 10.1002/jcb.24940 Mankin, 1980, The biology of human chondrosarcoma. II. Variation in chemical composition among types and subtypes of benign and malignant cartilage tumors, JBJS, 62, 176, 10.2106/00004623-198062020-00003 Marcove, 1982, A 17-year review of cryosurgery in the treatment of bone tumors, Clin. Orthop., 163, 231, 10.1097/00003086-198203000-00035 Meads, 2008, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance, Clin. Cancer Res., 14, 2519, 10.1158/1078-0432.CCR-07-2223 Mitchell, 2000, Experience in the treatment of dedifferentiated chondrosarcoma, Bone Jt. J., 82, 55, 10.1302/0301-620X.82B1.9020 Moussavi-Harami, 2006, Intrinsic radiation resistance in human chondrosarcoma cells, Biochem. Biophys. Res. Commun., 346, 379, 10.1016/j.bbrc.2006.05.158 Murphey, 2003, From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation, Radiographics, 23, 1245, 10.1148/rg.235035134 Nooter, 1991, Multidrug resistance (mdr) genes in human cancer, Br. J. Cancer, 63, 663, 10.1038/bjc.1991.152 Oshiro, 1998, Altered p53 is associated with aggressive behavior of chondrosarcoma, Cancer, 83, 2324, 10.1002/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U Palmini, 2017, What Is New in the miRNA world regarding osteosarcoma and chondrosarcoma?, Molecules, 22, 417, 10.3390/molecules22030417 Pan, 2015, MiR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma, Oncotarget, 6, 32805, 10.18632/oncotarget.5352 Peterse, 2017, NAD synthesis pathway interference Is a viable therapeutic strategy for chondrosarcoma, Mol. Cancer Res., 10.1158/1541-7786.MCR-17-0293 Polychronidou, 2017, Novel therapeutic approaches in chondrosarcoma, Future Oncol., 13, 637, 10.2217/fon-2016-0226 Reumann, 2016, Inhibition of autophagy increases 2-methoxyestradiol-induced cytotoxicity in SW1353 chondrosarcoma cells, J. Cell. Biochem., 117, 751, 10.1002/jcb.25360 Rozeman, 2005, Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas, J. Pathol., 205, 476, 10.1002/path.1723 Sampath, 2015, Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer, Pharmacol. Therap., 151, 16, 10.1016/j.pharmthera.2015.02.004 Schrage, 2009, Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment, Cancer Res., 69, 6216, 10.1158/0008-5472.CAN-08-4801 Schrage, 2010, COX-2 expression in chondrosarcoma: a role for celecoxib treatment?, Eur. J. Cancer, 46, 616, 10.1016/j.ejca.2009.11.002 Schwartz, 1987, The malignant potential of enchondromatosis, JBJS, 69, 269, 10.2106/00004623-198769020-00016 Simard, 2017, Description of the immune microenvironment of chondrosarcoma and contribution to progression, Oncoimmunology, 6, 10.1080/2162402X.2016.1265716 Smith, 2003, Aromatase inhibitors in breast cancer, N. Engl. J. Med., 348, 2431, 10.1056/NEJMra023246 Song, 2014, Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin, Tumour Biol., 35, 7017, 10.1007/s13277-014-1902-4 Stacchiotti, 2014, Activity of sunitinib in extraskeletal myxoid chondrosarcoma, Eur. J. Cancer, 50, 1657, 10.1016/j.ejca.2014.03.013 Streitbürger, 2009, Grade I chondrosarcoma of bone: the münster experience, J. Cancer Res. Clin. Oncol., 135, 543, 10.1007/s00432-008-0486-z Subbiah, 2012, Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist, Mol. Cancer Therap., 11, 2541, 10.1158/1535-7163.MCT-12-0358 Suit, 1982, Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine, J. Neurosurg., 56, 377, 10.3171/jns.1982.56.3.0377 Sun, 2015, MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells, Clin. Orthop. Relat. Res., 473, 907, 10.1007/s11999-014-3842-0 Tang, 2016, miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism, Drug. Des. Devel Ther., 10, 571 Tateishi, 2015, Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion, Cancer Cell., 28, 773, 10.1016/j.ccell.2015.11.006 Tiet, 2006, Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation, Am. J. Pathol., 168, 321, 10.2353/ajpath.2006.050001 Tomek, 2003, Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines, Eur. J. Cancer, 39, 1318, 10.1016/S0959-8049(03)00227-2 Tsai, 2015, Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells, Oncotarget, 6, 258, 10.18632/oncotarget.2724 Van Der Geest, 2008, Oncological and functional results of cryosurgical therapy of enchondromas and chondrosarcomas grade 1, J. Surg. Oncol., 98, 421, 10.1002/jso.21122 van Oosterwijk, 2013, Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals bcl-2 family members and TGFbeta as potential targets, Am. J. Pathol., 182, 1347, 10.1016/j.ajpath.2012.12.036 van Oosterwijk, 2013, Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells, Br J Cancer, 109, 1214, 10.1038/bjc.2013.451 Veth, 2005, Cryosurgery in aggressive, benign, and low-grade malignant bone tumours, Lancet Oncol., 6, 25, 10.1016/S1470-2045(05)70023-1 Wakatsuki, 2012, Differential bystander signaling between radioresistant chondrosarcoma cells and fibroblasts after x-ray, proton, iron ion and carbon ion exposures, Int. J. Radiat. Oncol. Biol. Phys., 84, e103, 10.1016/j.ijrobp.2012.02.052 Wirbel, 2000, Chondrosarcoma of the pelvis: oncologic and functional outcome, Sarcoma, 4, 161, 10.1155/2000/635246 Wyman, 1999, Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance, J. Orthop. Res., 17, 935, 10.1002/jor.1100170619 Xu, 2016, MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating beclin-1-mediated autophagy, Oncol. Rep., 35, 1757, 10.3892/or.2015.4497 Yao, 2014, Large intervening non-coding RNA HOTAIR is an indicator of poor prognosis and a therapeutic target in human cancers, Int. J. Mol. Sci., 15, 18985, 10.3390/ijms151018985 Yoshitaka, 2013, Analysis of microRNAs expressions in chondrosarcoma, J. Orthop. Res., 31, 1992, 10.1002/jor.22457 Zheng, 2010, Role of microRNA in anticancer drug resistance, Int. J. Cancer, 126, 2, 10.1002/ijc.24782 Zhu, 2014, MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR, Asian Pac. J. Cancer Prev., 15, 917, 10.7314/APJCP.2014.15.2.917 Zhu, 2015, Histone deacetylase inhibitors repress chondrosarcoma cell proliferation, J. BUON, 20, 269